BioCentury
ARTICLE | Clinical News

IMAB362: Phase IIa data

June 2, 2014 7:00 AM UTC

Data from 21 patients with advanced gastroesophageal cancer in the per protocol (PP) population of an open-label, European Phase IIa trial showed that 600 mg/m 2 IMAB362 as monotherapy every 2 weeks f...